(Oslo, 27. July 2016) Genetic Analysis AS today announces that it has been granted a US patent (Patent No. 9376724) for a method for identifying neonates at risk for necrotizing enterocolitis.
NEC is a gastrointestinal (GI) tract emergency where portions of the bowel undergo necrosis, but severe cases can cause profound impairment of multiple organ systems. About 10% of neonates weighing less than 1500 g are affected, although full term neonatals can also be affected.
The patented method comprises profiling the microbiota of the GI tract of a neonatal subject before onset of the condition and preferably as soon after birth as it is possible to detect microorganisms in a GI tract sample from the subject. That profile is then correlated either with standard profiles from neonatal subjects with NEC or which developed NEC and/or with standard profiles from neonatal subjects which did not develop NEC.
Genetic Analysis CEO Ronny Hermann commented: “The approval of this patent application highlights another unique approach of the GA technology in the emerging field of gut microbiota testing”
Mobile: +47 924 56 704
About Genetic Analysis
Genetic Analysis has developed and launched the first gene-based routine test for the mapping and diagnosis of diseases related to dysbiosis and imbalances in the bacteria in the digestive system. The company markets the GA-map™ technology to three market segments: commercial routine testing, pharma companies and the research market. Genetic Analysis was established in 2008 and is based on research done by Professor Knut Rudi at Norwegian University of Life Sciences, NMBU and Nofima Mat in Ås.
Comments are closed.